$3,019 Mln
$-357 Mln
--
As on 22-Sep-2023 16:10 EDT
$-0.17
•
-2.03%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| 30.89 | -2.72 | 11.53 | 15.77 | -20.76 | -19.89 | -22.44 |
|
S&P BSE Healthcare*
| 20.70 | -0.35 | 11.63 | 21.21 | 13.61 | 12.88 | 11.60 |
|
S&P Small-Cap 600#
| -0.96 | -4.96 | -1.70 | 6.06 | 11.51 | 1.45 | 6.57 |
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| -77.25 | 32.74 | -30.48 | 61.99 | -11.06 | 43.11 | -85.72 |
|
S&P Small-Cap 600
| -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 | 24.74 |
|
S&P BSE Healthcare
| -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 | -12.88 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Bausch Health Companies Inc. (BHC) stood at $ 29,368 Mln as on 31-Mar-23
The share price of Bausch Health Companies Inc. (BHC) is $8.220000 (NYSE) as of 22-Sep-2023 16:10 EDT. Bausch Health Companies Inc. (BHC) has given a return of -20.76% in the last 3 years.
Bausch Health Companies Inc. (BHC) has a market capitalisation of $ 3,019 Mln as on 19-May-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bausch Health Companies Inc. (BHC) is 18.78 times as on 19-May-2023, a 5.66% premium to its peers’ median range of 2.82 times.
Since, TTM earnings of Bausch Health Companies Inc. (BHC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bausch Health Companies Inc. (BHC) and enter the required number of quantities and click on buy to purchase the shares of Bausch Health Companies Inc. (BHC).
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
The CEO & director of Mr. Thomas J. Appio. is Bausch Health Companies Inc. (BHC), and CFO & Sr. VP is Mr. Thomas G. Vadaketh.
The promoters of Bausch Health Companies Inc. (BHC) have pledged 0% of the total equity as on Dec-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
571
|
|
|
71
|
|
|
1
|
|
|
0
|
| Bausch Health Companies Inc. (BHC) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
-25.26
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Bausch Health Companies Inc. (BHC) was $-357 Mln.
$3,018.91 Mln
$8,150.00 Mln
$-357.00 Mln
$518.00 Mln
$20,653.00 Mln
High
$5.57 - 10.23
363,724,000
NYSE: BHC
Laval, QC
https://www.bauschhealth.com
Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye... health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
